氢化可的松对严重脓毒症患者休克发生的影响:HYPRESS随机临床试验
这项双盲随机临床试验在德国34个中级或重症监护病房纳入380例未发生感染性休克的严重脓毒症成人,1:1随机接受氢化可的松连续输注200 mg共5天随后减量至第11天(n=190)或安慰剂(n=190)。主要终点14天内感染性休克发生在氢化可的松组170例中36例(21.2%)、安慰剂组170例中39例(22.9%),差异-1.8%(95%CI -10.7%至7.2%,P=.70)。ICU或医院死亡率、28天、90天、180天死亡率及至休克时间均无显著差异;氢化可的松组高血糖90.9% vs 81.5%、肌无力30.7% vs 23.8%、继发感染21.5% vs 16.9%。作者结论认为这些发现不支持在未发生休克的严重脓毒症患者中使用氢化可的松。
要点
- 未发生感染性休克的严重脓毒症成人中,氢化可的松200 mg连续输注5天随后减量至第11天,14天内感染性休克发生率21.2% vs 安慰剂22.9%,差异-1.8%(95%CI -10.7%至7.2%,P=.70)。
- 28天死亡率氢化可的松组8.8% vs 安慰剂组8.2%,差异0.5%(95%CI -5.6%至6.7%,P=.86),无显著差异。
- 180天死亡率氢化可的松组26.8% vs 安慰剂组22.2%,差异4.6%(95%CI -4.6%至13.7%,P=.32),无显著差异。
- 氢化可的松组高血糖90.9% vs 安慰剂组81.5%,肌无力30.7% vs 23.8%,继发感染21.5% vs 16.9%。
- 作者结论认为这些发现不支持在未发生感染性休克的严重脓毒症患者中使用氢化可的松。
适用人群与场景
- 德国34个中级或重症监护病房的380例成人严重脓毒症患者,未处于感染性休克状态。
处置流程与药物剂量
- 氢化可的松组:连续输注氢化可的松200 mg共5天,随后减量至第11天。
- 安慰剂组:接受安慰剂。
研究设计与关键结果
- 双盲随机临床试验,纳入380例未发生感染性休克的严重脓毒症成人,1:1随机接受氢化可的松连续输注200 mg共5天随后减量至第11天(n=190)或安慰剂(n=190);意向治疗人群353例(64.9%男性,平均年龄65.0岁,SD 14.4)。
- 主要终点14天内感染性休克:氢化可的松组170例中36例(21.2%) vs 安慰剂组170例中39例(22.9%),差异-1.8%(95%CI -10.7%至7.2%,P=.70)。
- 至感染性休克时间、ICU或医院死亡率无显著差异;28天死亡率氢化可的松组15/171(8.8%) vs 安慰剂组14/170(8.2%),差异0.5%(95%CI -5.6%至6.7%,P=.86);90天死亡率34/171(19.9%) vs 28/168(16.7%),差异3.2%(95%CI -5.1%至11.4%,P=.44);180天死亡率45/168(26.8%) vs 37/167(22.2%),差异4.6%(95%CI -4.6%至13.7%,P=.32)。
- 氢化可的松组 vs 安慰剂组:继发感染21.5% vs 16.9%,脱机失败8.6% vs 8.5%,肌无力30.7% vs 23.8%,高血糖(血糖>150 mg/dL)90.9% vs 81.5%。
证据类型、等级与局限
- 证据类型:双盲随机临床试验(HYPRESS),clinicaltrials.gov注册号NCT00670254。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为这些发现不支持在未发生感染性休克的严重脓毒症成人中使用氢化可的松。
- 拯救脓毒症运动仅建议在难治性感染性休克中使用氢化可的松辅助治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Adjunctive hydrocortisone therapy is suggested by the Surviving Sepsis Campaign in refractory septic shock only. The efficacy of hydrocortisone in patients with severe sepsis without shock remains controversial.
OBJECTIVE: To determine whether hydrocortisone therapy in patients with severe sepsis prevents the development of septic shock.
DESIGN, SETTING, AND PARTICIPANTS: Double-blind, randomized clinical trial conducted from January 13, 2009, to August 27, 2013, with a follow-up of 180 days until February 23, 2014. The trial was performed in 34 intermediate or intensive care units of university and community hospitals in Germany, and it included 380 adult patients with severe sepsis who were not in septic shock.
INTERVENTIONS: Patients were randomly allocated 1:1 either to receive a continuous infusion of 200 mg of hydrocortisone for 5 days followed by dose tapering until day 11 (n = 190) or to receive placebo (n = 190).
MAIN OUTCOMES AND MEASURES: The primary outcome was development of septic shock within 14 days. Secondary outcomes were time until septic shock, mortality in the intensive care unit or hospital, survival up to 180 days, and assessment of secondary infections, weaning failure, muscle weakness, and hyperglycemia (blood glucose level >150 mg/dL [to convert to millimoles per liter, multiply by 0.0555]).
RESULTS: The intention-to-treat population consisted of 353 patients (64.9% male; mean [SD] age, 65.0 [14.4] years). Septic shock occurred in 36 of 170 patients (21.2%) in the hydrocortisone group and 39 of 170 patients (22.9%) in the placebo group (difference, -1.8%; 95% CI, -10.7% to 7.2%; P = .70). No significant differences were observed between the hydrocortisone and placebo groups for time until septic shock; mortality in the intensive care unit or in the hospital; or mortality at 28 days (15 of 171 patients [8.8%] vs 14 of 170 patients [8.2%], respectively; difference, 0.5%; 95% CI, -5.6% to 6.7%; P = .86), 90 days (34 of 171 patients [19.9%] vs 28 of 168 patients [16.7%]; difference, 3.2%; 95% CI, -5.1% to 11.4%; P = .44), and 180 days (45 of 168 patients [26.8%] vs 37 of 167 patients [22.2%], respectively; difference, 4.6%; 95% CI, -4.6% to 13.7%; P = .32). In the hydrocortisone vs placebo groups, 21.5% vs 16.9% had secondary infections, 8.6% vs 8.5% had weaning failure, 30.7% vs 23.8% had muscle weakness, and 90.9% vs 81.5% had hyperglycemia.
CONCLUSIONS AND RELEVANCE: Among adults with severe sepsis not in septic shock, use of hydrocortisone compared with placebo did not reduce the risk of septic shock within 14 days. These findings do not support the use of hydrocortisone in these patients.
TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00670254.
参考来源
- Keh D, Trips E, Marx G, et al. Effect of Hydrocortisone on Development of Shock Among Patients With Severe Sepsis: The HYPRESS Randomized Clinical Trial. JAMA. 2016. PMID: 27695824. doi:10.1001/jama.2016.14799
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。